Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05325281 · ClinicalTrials.gov registry record · Phase 1
CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05325281 is a Phase 1 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 8 participants.
The verdict
NCT05325281, a Phase 1 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single-center, open-label, phase I study designed to determine the maximum tolerated dose (MTD) and safety profile of CPI-613® when used concomitantly with chemoradiation for local control of pancreatic adenocarcinoma (PDAC).
Interventions
- DRUG CPI-613® (Dose level -1.0 250 mg/m^2)
- DRUG CPI-613® (Dose level 1.0 500 mg/m^2)
- DRUG CPI-613® (Dose level 2.0 1,000 mg/m^2)
- DRUG CPI-613® (Dose level 3.0 1,500 mg/m^2)
- DRUG CPI-613® Maximum Tolerated Dose (MTD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2025-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05325281
The ClinicalTrials.gov registry entry for NCT05325281 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CPI-613® (Dose level -1.0 250 mg/m^2) is the first listed.
NCT05325281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05325281 about?
NCT05325281 is a clinical study titled "CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma". This is a single-center, open-label, phase I study designed to determine the maximum tolerated dose (MTD) and safety profile of CPI-613® when used concomitantly with chemoradiation for local control of pancreatic adenocarcinoma (PDAC).
What is the current status of trial NCT05325281?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-10-31. Estimated completion is 2025-07-08.
What interventions are being tested in trial NCT05325281?
The interventions under investigation include: CPI-613® (Dose level -1.0 250 mg/m^2) (DRUG), CPI-613® (Dose level 1.0 500 mg/m^2) (DRUG), CPI-613® (Dose level 2.0 1,000 mg/m^2) (DRUG), CPI-613® (Dose level 3.0 1,500 mg/m^2) (DRUG), CPI-613® Maximum Tolerated Dose (MTD) (DRUG).
Who is sponsoring clinical trial NCT05325281?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.